Statin expression in the untreated and SarCNU-exposed human glioma cell line,SK-MG-1 |
| |
| Authors: | Hyman M. Schipper Violetta Skalski Lawrence C. Panasci Eugenia Wang |
| |
| Affiliation: | (1) Department of Neurology, Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis Jewish General Hospital, Canada;(2) Department Oncology, Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis Jewish General Hospital, Canada;(3) Bloomfield Centre for Aging, Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis Jewish General Hospital, Canada;(4) Department of Anatomy and Medicine, McGill University, Montreal, Quebec, Canada;(5) Lady Davis Institute for Medical Research, Sir Mortimer B. Davis — Jewish General Hospital, 3755 Cote Ste-Catherine Road, H3T 1E2 Montreal, QC, Canada |
| |
| Abstract: | Summary Cytokinetic analyses of gliomas and other neoplasms rely exclusively on the use of proliferation-dependent markers such as [3H]-thymidine and BuDR incorporation and the detection of growth-dependent proteins such as proliferating cell nuclear antigen (PCNA) and Ki-67. In normal tissues, the monoclonal antibody S-44 recognizes statin, a nuclear protein expressed only in nonproliferating cells. In the present study, indirect immunofluorescence microscopy using S-44 identified nuclear statin in 5.9% of a population of untreated human SK-MG-1 glioma cells in vitro. Incremental doses of the alkylating agent sarcosinamide chloroethylnitrosourea (SarCNU) induced a linear increase in the fraction of statin-positive SK-MG-1 cells. Labeling of nuclear statin with the monoclonal antibody S-44 may be a potentially useful marker of the cytotoxic effects of anticancer drugs in gliomas and other neoplastic tissues. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
